Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atrial fibrillation.

Caroline Medi1, Graeme J Hankey, Saul B Freedman

  • 1Department of Cardiology, Concord Repatriation General Hospital, University of Sydney, Sydney, NSW. ben@gmp.usyd.edu.au.

The Medical Journal of Australia
|February 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Focused Transthoracic Echocardiogram Surveillance Protocol for Hypertrophic Cardiomyopathy Patients on Mavacamten Therapy.

Heart, lung & circulation·2026
Same author

Screening families after sudden cardiac death in the young: do we ever stop?

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

Recurrent immunosuppressive-responsive myocarditis in a patient with desmoplakin cardiomyopathy: a case report.

European heart journal. Case reports·2024
Same author

Longitudinal assessment of structural phenotype in Brugada syndrome using cardiac magnetic resonance imaging.

Heart rhythm O2·2023
Same author

The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic.

Genome medicine·2022
Same author

Cardiac Society of Australia and New Zealand (CSANZ) Position Statement on the Follow-Up of Cardiovascular Implantable Electronic Devices 2022.

Heart, lung & circulation·2022
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
Same journal

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

The Medical journal of Australia·2026
Same journal

Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

The Medical journal of Australia·2026
Same journal

Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

The Medical journal of Australia·2026
See all related articles

Atrial fibrillation management involves rate or rhythm control, with medication choices guided by patient factors. Optimal stroke prevention relies on the CHADS2 score, recommending warfarin for higher-risk patients and aspirin for lower-risk individuals.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • The incidence and prevalence of atrial fibrillation (AF) are rising due to population aging and increased age-adjusted incidence.
  • Management decisions for AF, including rate or rhythm control, are influenced by patient age, comorbidities, symptoms, and hemodynamic status.

Purpose of the Study:

  • To review current strategies for managing atrial fibrillation, focusing on rate versus rhythm control and antithrombotic prophylaxis.
  • To provide guidance on selecting appropriate medications for rate control and optimizing stroke risk assessment and prevention in AF patients.

Main Methods:

  • Literature review of studies on atrial fibrillation management, rate control, rhythm control, and antithrombotic therapies.
  • Analysis of current guidelines and evidence regarding drug efficacy and safety for AF treatment.

Related Experiment Videos

  • Evaluation of stroke risk stratification tools, specifically the CHADS2 score, for guiding antithrombotic selection.

    • Main Results:

    • Beta-blockers, verapamil, and diltiazem are preferred for rate control over digoxin, especially during exercise.
    • Anti-arrhythmic drugs have limited long-term success (40%-60% at 1 year) and significant side effects.
    • The CHADS2 score effectively estimates ischemic stroke risk, guiding antithrombotic choices.
    • Warfarin is recommended for patients with valvular AF or CHADS2 score ≥2, while aspirin may be suitable for lower-risk patients.
    • Stroke rates are comparable across different AF types (paroxysmal, persistent, permanent) and likely atrial flutter.

    Conclusions:

    • Either rate or rhythm control is acceptable for AF management, with choices individualized.
    • Antithrombotic prophylaxis selection is independent of rate/rhythm control strategy and primarily based on stroke risk assessed by the CHADS2 score.
    • Warfarin is indicated for high-risk patients, while aspirin is an option for those with lower stroke risk or contraindications to warfarin.